ASH Research Collaborative to Present Data at 67th ASH Annual Meeting and Exposition
Presentations highlight how real-world data accelerate research and improve hematology care.
ASH Research Collaborative News
Accelerating Novel Therapies for Sickle Cell Disease with RWE: ASH RC Data Hub as a Strategically Coordinated Registry Network
Real-world evidence (RWE) has been used to improve quality of care, accelerate innovation, and evaluate emerging therapies for drugs, devices, and biologics. The Coordinated Registry Network (CRN), aggregating and linking highly curated patient data, has emerged as a model for RWE generation that has guided the development of the ASH Research Collaborative® (ASH RC) Data Hub. With the aim of bolstering research, enhancing clinical care, and expediting evidence generation using RWE, ASH RC, and the Innovative Genomics Institute (IGI) launched a joint initiative, “Accelerating Innovations for Sickle Cell Disease (SCD) with Real-World Evidence,” to evaluate and make recommendations to the Data Hub.
ASH Research Collaborative (ASH RC) Sickle Cell Disease (SCD) Data Hub Award
Sickle cell disease (SCD), a condition that remains widely misunderstood, underresearched, and underfunded, is the most common inherited blood disorder, affecting an estimated 100,000 people in the United States.
ASH Research Collaborative’s Real-World Evidence Consortium for SCD Goes Live with Duke Clinical Research Institute
Sickle cell disease (SCD), a condition that remains widely misunderstood, underresearched, and underfunded, is the most common inherited blood disorder, affecting an estimated 100,000 people in the United States.
An Agenda for Sickle Cell Disease Research That Encompasses Lived Experience
Sickle cell disease (SCD), a condition that remains widely misunderstood, underresearched, and underfunded, is the most common inherited blood disorder, affecting an estimated 100,000 people in the United States.
Request for Applications (RFA) Open
The ASH Research Collaborative (ASH RC) Data Hub’s Multiple Myeloma Program can feasibly collect patient data from its participating sites for prospective evidence generation, according to new research presented at the 66th ASH Annual Meeting and Exposition.
Filing the Gaps: The Urgent Need for Sickle Cell Disease Data
Sickle cell disease (SCD), a condition that remains widely misunderstood, underresearched, and underfunded, is the most common inherited blood disorder, affecting an estimated 100,000 people in the United States.
ASH RC Data Hub’s Multiple Myeloma Program Accelerates Research
The ASH Research Collaborative (ASH RC) Data Hub’s Multiple Myeloma Program can feasibly collect patient data from its participating sites for prospective evidence generation, according to new research presented at the 66th ASH Annual Meeting and Exposition.
Innovative ASH RC Study Quickly, Effectively Generates COVID-19 Data in Patients with Multiple Myeloma
An innovative study of patients with multiple myeloma rapidly accrued a diverse cohort, demonstrated high consent/adherence rates, and assessed COVID-19 outcomes and their impact on quality of life. The research was presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California, and online.
ASH RC Data Hub Accurately Confirms SCD Diagnosis Type
The ASH Research Collaborative (ASH RC) Data Hub, which was developed to facilitate research and quality improvement through real-world data, accurately correlates sickle cell disease (SCD) genotype with verified diagnoses, validating existing and future clinical data in the ASH RC’s Data Hub, according to new research presented today at the 66th ASH Annual Meeting and Exposition.
ASH RESEARCH COLLABORATIVE
The ASH Research Collaborative (ASH RC) is a non-profit organization established by the American Society of Hematology (ASH) in 2017 to improve the lives of people affected by blood diseases by fostering collaborative partnerships to accelerate progress in hematology. Learn more about ASH RC